

Ivan Poullaos Discusses How the Supreme Court's Enablement Ruling in *Amgen v. Sanofi* Will Affect Biologic Patent Portfolio Strategies

JUNE 27-28, 2023

Winston & Strawn Partner Ivan Poullaos will speak at the 14th Summit on Biosimilars & Innovator Biologics, June 27-28, in Boston. The summit—which attracts the “who’s who” of the industry, including leading in-house counsel from branded and biosimilar companies; representatives from key government agencies; and the top patent and regulatory attorneys—will cover legal, regulatory, and commercial strategies for the innovator and biosimilars marketplace.

Ivan’s panel “*Amgen v. Sanofi*: Anticipating How the Supreme Court’s Enablement Ruling Will Affect Biologic Patent Portfolio Strategies” will discuss:

- Devising alternate strategies for drafting enforceable claims
- Outlining the scope of appropriate claims for antibodies
- Implementing new strategies for drafting enforceable claims in view of the Supreme Court’s decision
- Understanding the nuances between written description and enablement
- Why did the Supreme Court decline to hear *Kite v. Juno*?
- Reconciling whether written description is met when the specification discloses formulas

[Learn more and register here.](#)

[Learn more about Winston’s Patent Litigation Practice here.](#)

1 Min Read

Related Locations

Chicago

Related Capabilities

Intellectual Property

Patent Litigation

Medical Devices

Health Care

Related Regions

North America

Related Professionals



Ivan Poullaos